vaccine-development
(2)
The Tiny Vaccine Lab With a $10 Million Head Start - and No Human Trial Yet
TechnoVax has spent two decades making convincing copies of dangerous viruses - minus the genes that make them dangerous. Its science has attracted roughly $10 million in federal awards; the harder experiment is turning a tiny lab's preclinical wins into a product people can actually receive.
ArkeaBio
ArkeaBio is a Boston climate-biotech company building the first vaccine that cuts methane emissions from cattle. The shot trains a cow's immune system to produce antibodies that travel to the rumen and suppress methanogens - the microbes that turn digestion into greenhouse gas. Livestock methane accounts for roughly 6% of global emissions, and ArkeaBio's pitch is blunt: a vaccine is the lowest-cost, most scalable way to attack that number. Backed by Breakthrough Energy Ventures and a roster of climate and ag investors, the company is moving from animal studies into full field trials, targeting a 20% methane reduction and a first product in market around 2028.